←
Sean Sachdev, MD1,665 posts
Sean Sachdev, MD avatar✓

Sean Sachdev, MD ✓

@SeanSachdevMD

Radiation Oncologist, Associate Professor at @NorthwesternMed @LurieCancer. #radonc #btsm #pcsm tweets = own opinion

◷ Joined April 2017▧ 180 Photos and videos
Sia Daneshmand, M.D. avatar
⟳ Sean Sachdev, MD retweeted
Sia Daneshmand, M.D.@siadaneshmand·Jul 11

Let’s not forget the BRIGHT trial (@SWOG S2427) -Phase II study evaluating a bladder-preservation strategy for patients with #MIBC who achieve a meaningful response to neoadjuvant therapy—using pembrolizumab + radiation instead of immediate radical cystectomy in carefully selected patients. @l_ballas @AbhiTrip87 @MarkTysonMD @mouwlab @JoshMeeks @djmcconkey @KyleRoseMD @DrKarineTawagi @SeanSachdevMD @kritimittalmd

NEJM avatar
⟳ Sean Sachdev, MD retweeted
NEJM@NEJM·Mar 10

Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…

Post attachment
Chad Tang, MD avatar
⟳ Sean Sachdev, MD retweeted
Chad Tang, MD@ChadTangMD·Feb 3

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

Dr. Jason Efstathiou avatar
⟳ Sean Sachdev, MD retweeted
Dr. Jason Efstathiou@drjefstathiou·Jan 24

Great to reconnect with so many motivated clinical trialists, colleagues, and the #GU family at the @NRGOnc Winter Meeting #NRG2026! 2025 was a big year for NRG GU with landmark trials presented at ASTRO in plenary and clinical trials sessions (GU005, RTOG 0924, GU006) and two major bladder trials that were launched: 🔹 NRG GU014 PARRC 💉 — RT+IO vs chemoRT in NMIBC 🔹 NRG GU015 ARCHER 🏹 — 20 vs 5 (adaptive) fractions chemoRT in MIBC Lots more to come in 2026! Grateful to the PIs and study teams—and especially to the patients and families who make NRG trials possible. @snseyedinMD @jmmrad @DrHowardSandler @NehaVapiwala @DrPaulNguyen @RonaldChenMD @MaryFengMD @ChadTangMD @KHoffmanMD @BrianBaumannMD @CaPsurvivorship @EdwinPosadasMD @MiyamotoDavid @abhiAsolanki @bridget_koontz @MoningiShalini @HimanshuNagarMD @UroCancer @DrSpratticus @Katie_Spina @TylerSbrt @sophia_kamran @tranpt21 @aleberlin2 @a_dalpra @ndesai2005 @SeanSachdevMD @MassGenBrigham @NRGonc #NRGOncology #RadiationOncology #GUCancer #CancerResearch #OncologyCommunity #BladderCancer #ClinicalTrials #TeamScience

Post attachmentPost attachmentPost attachment
Dr. Jason Efstathiou avatar
⟳ Sean Sachdev, MD retweeted
Dr. Jason Efstathiou@drjefstathiou·19 Aug 2025

🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER) Congratulations to the NRG GU015 ARCHER study team led by @UroCancer and @HimanshuNagarMD for the recent activation and launch of this cutting-edge and patient-centric bladder-sparing phase III trial that investigates many novel interventions including ultrahypofractionation/SBRT, adaptive radiation, ctDNA as a biomarker, and allows for any neoadjuvant systemic therapy. Please support this important study! #CancerResearch #RadiationOncology #Urology #MedicalOncology #MIBC #ClinicalTrial #ClinicalResearch @DrPaulNguyen @Shilpaonc @danielxingao @SeanSachdevMD @KellyStratton @AdityaBagrodia @ndesai2005 @Jonathan_Leeman @KashaniRojano @KateMRGuidance @DrMBWesterman @abhiAsolanki @MiyamotoDavid @Katie_Spina @jamesmgtsui @NRGOnc @MGHCancerCenter @urotoday @BladderCancerUS @MassGenBrigham

Post attachmentPost attachment
Dr. Jason Efstathiou avatar
⟳ Sean Sachdev, MD retweeted
Dr. Jason Efstathiou@drjefstathiou·27 Sep 2024

On Monday, I will present the key PARTIQoL trial results at the 2024 @ASTRO_org Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!

0:12
Sean Sachdev, MD avatar
Sean Sachdev, MD@SeanSachdevMD·10 Jun 2024

Really honored and humbled to receive the 2024 Christopher Getch Clinical Excellence Award from @NeurosurgeryNM Proud to participate in the care of brain tumor patients and contribute to the education of neurosurgery residents #btsm

Post attachment
PDBrown avatar
⟳ Sean Sachdev, MD retweeted
PDBrown@PDBrownOnc·2 Oct 2023

ASTRO PLENARY Session LBA 04 Randomized trial PCI vs HA-PCI: HA-PCI is a standard of care for Small cell lung cancer

Post attachment